Justin Chakma
CIK: 0001951238
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
240K shares- - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct30K shares at avg. $8.91$267K - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct136.4K shares at avg. $8.86$1.2M - Nov 12, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct30K shares at avg. $0.84$25K - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
274.1K shares- - Dec 13, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct27.3K shares at avg. $1.44$39K - Dec 13, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct27.3K shares at avg. $12.06$329K - Dec 12, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct117.3K shares at avg. $0.84$99K - Dec 12, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct117.3K shares at avg. $12.27$1.4M - Dec 10, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $13.15$658K - Dec 10, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $0.84$42K - Dec 6, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $0.84$42K - Dec 6, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $14.23$712K - Dec 5, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct49.6K shares at avg. $0.84$42K - Dec 5, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct49.6K shares at avg. $14.13$702K - Dec 4, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct45K shares at avg. $13.95$628K - Dec 4, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct45K shares at avg. $0.84$38K - Dec 3, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct41.7K shares at avg. $0.84$35K - Dec 3, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct3.3K shares at avg. $0.84$3K - Dec 3, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct45K shares at avg. $13.19$593K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct45K shares at avg. $0.84$38K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct45K shares at avg. $13.67$615K - Nov 27, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct25K shares at avg. $14.39$360K - Nov 26, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct42.2K shares at avg. $14.05$593K - Nov 25, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct32.8K shares at avg. $14.00$459K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 240,000 | - | - | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 30,000 | $8.91 | $267,357 | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 136,380 | $8.86 | $1,208,790 | Direct |
| Nov 12, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 30,000 | $0.84 | $25,200 | Direct |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 274,100 | - | - | Direct |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 27,272 | $1.44 | $39,272 | Direct |
| Dec 13, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 27,272 | $12.06 | $328,969 | Direct |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 117,333 | $0.84 | $98,560 | Direct |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 117,333 | $12.27 | $1,439,124 | Direct |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $13.15 | $657,625 | Direct |
| Dec 10, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $0.84 | $42,000 | Direct |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $0.84 | $42,000 | Direct |
| Dec 6, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $14.23 | $711,615 | Direct |
| Dec 5, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 49,640 | $0.84 | $41,698 | Direct |
| Dec 5, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 49,640 | $14.13 | $701,642 | Direct |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 45,000 | $13.95 | $627,944 | Direct |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 45,000 | $0.84 | $37,800 | Direct |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 41,740 | $0.84 | $35,062 | Direct |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 3,260 | $0.84 | $2,738 | Direct |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 45,000 | $13.19 | $593,402 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 45,000 | $0.84 | $37,800 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 45,000 | $13.67 | $615,218 | Direct |
| Nov 27, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 25,000 | $14.39 | $359,750 | Direct |
| Nov 26, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 42,186 | $14.05 | $592,570 | Direct |
| Nov 25, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 32,814 | $14.00 | $459,422 | Direct |
1-25 of 25 transactions
About Chakma Justin
Chakma Justin (SEC CIK 0001951238) files insider reports with the SEC as Chief Business Officer of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 8 ownership filings by Chakma Justin, all Form 4s, filed between Nov 27, 2024 and Jan 5, 2026. Those filings report 25 transactions, from Nov 25, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Chakma Justin's filings is in SAN DIEGO, CA.
Recent filings by Chakma Justin
- Jan 2, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- Nov 12, 2025: Open-market sales of SPRY shares (2 lines, Form 4, code S).
- Nov 12, 2025: Option exercise of SPRY shares (Form 4, code M).
- Jan 2, 2025: Grant or award of SPRY derivative securities (Form 4, code A).
- Dec 13, 2024: Option exercise of SPRY shares (Form 4, code M).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Kelly Michael, Director